Editorial
Outcomes in Long‐Term Follow‐Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative
Annals of neurology
05/18/2026
DOI: 10.1002/ana.78248
PMID: 42152134
Abstract
The Parkinson's Progression Markers Initiative (PPMI) has addressed a key gap in the availability of long‐term longitudinal data in sporadic Parkinson's disease (sPD) with extensive biological characterization. With biological characterization in the neuronal synuclein disease (NSD) framework, longitudinal outcomes are observed in cohorts defined by biological characteristics rather than based on conventional clinical diagnostic criteria. We recently reported our observations on 5 years of follow up in this cohort, and here, we provide our earliest findings on a comprehensive long‐term description of disease progression in 344 sPD participants followed for up to 11 years. Although data collection is ongoing, these early findings highlight the heterogeneity in the early PD population as defined by clinical diagnostic criteria and affirm the importance of shifting to biologically and functionally based criteria in clinical research studies. ANN NEUROL 2026
Details
- Title: Subtitle
- Outcomes in Long‐Term Follow‐Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative
- Creators
- Paulina Gonzalez-Latapi - Northwestern UniversityCaroline Gochanour - University of IowaSeung Ho Choi - University of IowaHyunkeun Cho - University of California San DiegoChelsea Caspell-Garcia - University of IowaChristopher S. Coffey - University of IowaDavid‐Erick Lafontant - University of Iowa, BiostatisticsYuge Xiao - Michael J. Fox FoundationCaroline M. Tanner - University of California, San FranciscoCharles S. Venuto - University of RochesterKarl Kieburtz - University of RochesterLana M. Chahine - University of PittsburghKathleen L. Poston - Stanford UniversityDouglas Galasko - University of California San DiegoMarina Picillo - University of SalernoAndrew Siderowf - University of PennsylvaniaThomas F. Tropea - Institute for Neurodegenerative DisordersTanya Simuni - Northwestern UniversityKenneth Marek - Institute for Neurodegenerative DisordersParkinson's Progression Markers Initiative
- Resource Type
- Editorial
- Publication Details
- Annals of neurology
- DOI
- 10.1002/ana.78248
- PMID
- 42152134
- NLM abbreviation
- Ann Neurol
- ISSN
- 0364-5134
- eISSN
- 1531-8249
- Publisher
- Wiley
- Grant note
- Michael J. Fox Foundation for Parkinson's Research AbbVie BIAL Critical Path Institute Edmond J. Safra Foundation Eli Lilly, Gain Therapeutics GE HealthCare Voyager Therapeutics Weston Family Foundation Early Investigator Award from PPMI
PPMI-a public-private partnership-is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Alamar Biosciences, Aligning Science Across Parkinson's, Arrowhead Pharma, AskBio, BIAL, BioArctic, Biohaven, BlueRock Therapeutics, Bristol-MyersSquibb, Calico Labs, Capsida Biotherapeutics, Critical Path Institute, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Insitro, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Neumora, Neuron23, Novartis, Regeneron, Roche, Sanofi, Tenvie, UCB, VanquaBio, Voyager Therapeutics, and the Weston Family Foundation. P.G.L. is supported by an Early Investigator Award from PPMI.
- Language
- English
- Electronic publication date
- 05/18/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985164726902771
Metrics
1 Record Views